drugset / Trial / NCT00864305

A Relative Bioavailability Study of Gabapentin 400 mg Capsules Under Non-fasting Conditions

NCT00864305

Phase 1 Completed 18 enrolled Actavis Inc.
RandomizedCrossoverOpen-label

Summary

To compare the relative bioavailability of gabapentin 400 mg capsules (Purepac) with that of NEURONTIN® 400 mg capsules (Parke-Davis) in healthy adult male subjects under non-fasting conditions, and to compare the differences in plasma levels after dosing the test formulation with and without food

Timeline

Start
1997-12
Primary completion
1998-01
Completion
1998-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Gabapentin Small molecule 400 mg

Indications

No indication recorded.